| Style | Citing Format |
|---|---|
| MLA | Asadipour E, Kargar M. "Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease." International Journal of Clinical Pharmacy, vol. 42, no. 6, 2020, pp. 1521-1523. |
| APA | Asadipour E, Kargar M (2020). Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease. International Journal of Clinical Pharmacy, 42(6), 1521-1523. |
| Chicago | Asadipour E, Kargar M. "Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease." International Journal of Clinical Pharmacy 42, no. 6 (2020): 1521-1523. |
| Harvard | Asadipour E, Kargar M (2020) 'Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease', International Journal of Clinical Pharmacy, 42(6), pp. 1521-1523. |
| Vancouver | Asadipour E, Kargar M. Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease. International Journal of Clinical Pharmacy. 2020;42(6):1521-1523. |
| BibTex | @article{ author = {Asadipour E and Kargar M}, title = {Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease}, journal = {International Journal of Clinical Pharmacy}, volume = {42}, number = {6}, pages = {1521-1523}, year = {2020} } |
| RIS | TY - JOUR AU - Asadipour E AU - Kargar M TI - Drug Survival of Infliximab and Adalimumab in Inflammatory Bowel Disease JO - International Journal of Clinical Pharmacy VL - 42 IS - 6 SP - 1521 EP - 1523 PY - 2020 ER - |